Nutrition-based interventions for mood disorders.
Authors: Bhering Martins L, Braga Tibães JR, Sanches M, Jacka F, Berk M, Teixeira AL Abstract Introduction: 'Nutritional Psychiatry' is an emerging area of research that has great potential as an adjunctive tool for the prevention and treatment of diverse neuropsychiatric disorders. Several nutrition-related aspects, such as obesity, dietary patterns, gut microbiome composition and gut permeability, bioactive food compounds, and nutrients can influence pathways implicated in the pathophysiology of mood disorders. Areas covered: Here, the authors review the current evidence on nutrition-mood interaction and nutr...
Source: Expert Review of Neurotherapeutics - January 26, 2021 Category: Neurology Tags: Expert Rev Neurother Source Type: research

The therapeutic potential of ketone bodies in Parkinson's disease.
Authors: Thickbroom GW PMID: 33487081 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - January 26, 2021 Category: Neurology Tags: Expert Rev Neurother Source Type: research

A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome.
Authors: Schoonjans AS, Ceulemans B Abstract INTRODUCTION: Dravet Syndrome (DS) is a severe developmental and epileptic encephalopathy. Most patients develop a drug-resistant epilepsy. Fenfluramine recently demonstrated to be a highly efficacious and safe treatment option for DS patients. Fenfluramine has been recently approved by the FDA and marketed as Fintepla®. AREAS COVERED: : DS and the need for additional anticonvulsive treatment options is discussed. The results of three placebo-controlled phase III studies (1 with and 2 without stiripentol) and 2 open label (extension) studies are reviewed. All studies...
Source: Expert Review of Neurotherapeutics - January 20, 2021 Category: Neurology Tags: Expert Rev Neurother Source Type: research

A critical review of the capsaicin 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults.
Authors: Abrams RMC, Pedowitz EJ, Simpson DM Abstract INTRODUCTION: Diabetes is an increasingly prevalent disorder affecting nearly 1-in-5 adults, of which half will experience diabetic peripheral neuropathy (DPN) and a quarter will suffer from diabetic peripheral nerve pain (DPNP), severely impacting quality of life. The currently approved treatment options are typically centrally acting agents whose use is limited by systemic effects and drug interactions. The capsaicin 8% dermal patch was recently approved by the U.S. FDA for the treatment of DPNP. AREAS COVERED: The authors review the available literature regar...
Source: Expert Review of Neurotherapeutics - January 12, 2021 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Vitamin D in the Development and Progression of Alzheimer's Disease: Implications for Clinical Management.
Authors: Panza F, La Montagna M, Lampignano L, Zupo R, Bortone I, Castellana F, Sardone R, Borraccino L, Dibello V, Resta E, Altamura M, Daniele A, Lozupone M Abstract INTRODUCTION: Although the pathophysiological bases of Alzheimer's disease (AD) remain incompletely understood and disease-modifying therapies are not available, intervention on modifiable risk factors is warranted. Research on nutrition and dietary components is challenging and controversies still persist about the role of many micro- and macronutrients and health outcomes in dementia. Importantly, results of preclinical investigations have shown that ...
Source: Expert Review of Neurotherapeutics - January 8, 2021 Category: Neurology Tags: Expert Rev Neurother Source Type: research

The Insidious Impact of Under-Diagnosed Proximal Weakness Induced by Statins.
Authors: Dobkin BH Abstract Introduction: This Perspective reassesses the consensus opinion that statin-associated muscle symptoms (SAMS) occur in
Source: Expert Review of Neurotherapeutics - December 20, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Developing precision treatments for epilepsy using patient and animal models.
Authors: Ɓukawski K, Czuczwar SJ Abstract INTRODUCTION: Phenytoin was the first antiepileptic drug (AED) discovered in an animal model of seizures whose clinical efficacy was subsequently confirmed. This clearly indicated that a search for other AEDs had to consider animal studies. AREAS COVERED: Main seizure tests used for the evaluation of possible anticonvulsive activity of potential anticonvulsants and their predictive values have been reviewed. Procedures used for the estimation of antiepileptogenic effects have been also included. EXPERT OPINION: First-line seizure models comprise maximal electroshock (ME...
Source: Expert Review of Neurotherapeutics - December 20, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Can we use the dynamic and complex interplay between pain and sleep to quantify neuromodulation responsiveness for chronic pain?
Authors: Kinfe T, Buchfelder M, Stadlbauer A PMID: 33325751 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - December 17, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Management of status epilepticus in patients with liver or kidney disease: a narrative review.
Authors: Mastroianni G, Iannone LF, Roberti R, Gasparini S, Ascoli M, Cianci V, De Sarro G, Gambardella A, Labate A, Brigo F, Russo E, Aguglia U, Ferlazzo E Abstract INTRODUCTION: Status epilepticus (SE) is a neurologic and medical emergency with significant related morbidity and mortality. Hepatic or renal dysfunction can considerably affect the pharmacokinetics of drugs used for SE through a variety of direct or indirect mechanisms. AREAS COVERED: This review aims to focus on the therapeutic management of SE in patients with hepatic or renal impairment, highlighting drugs' selection and dose changes that may be n...
Source: Expert Review of Neurotherapeutics - December 12, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Novel therapeutic options for Dravet and Lennox-Gastaut syndrome.
Authors: Verrotti A, Striano P PMID: 33297778 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - December 12, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Evaluating and managing severe headache in the emergency department.
Authors: Luciani M, Negro A, Spunatrelli V, Bentivegna E, Martelletti P Abstract INTRODUCTION: Headache is the fifth most common reason to visit an emergency department (ED). In most of the cases headache is benign and has a primary origin, with migraine as the most common diagnosis. Inappropriate use of ED for non-emergency conditions causes overcrowding, unnecessary testing and increased medical costs. AREAS COVERED: All stages of headache management in ED, from the reasons to go there, the diagnosis that is made and the investigations necessary to make it, to get to the therapies administered and those prescribe...
Source: Expert Review of Neurotherapeutics - December 12, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Polyamines serum levels in episodic and chronic migraine.
CONCLUSIONS: The authors suggest that alterations of polyamines levels might contribute to the understanding of migraine external activation and help to clarify the potential role of NMDA receptor polyamines site antagonists in migraine treatment. PMID: 33295216 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - December 10, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Nutraceutical Induction and Mimicry of Heme Oxygenase Activity as a Strategy for Controlling Excitotoxicity in Brain Trauma and Ischemic Stroke: Focus on Oxidative Stress.
Authors: McCarty MF, Lerner A Abstract Introduction: Ischemic stroke and traumatic brain injury are leading causes of acute mortality, and in the longer run, major causes of significant mental and physical impairment. Most of the brain neuronal cell death in the minutes and hours following an ischemic stroke or brain trauma is mediated by the process of excitotoxicity, in which sustained elevations of extracellular glutamate, reflecting a failure of ATP-dependent mechanism which sequester glutamate in neurons and astrocytes, drive excessive activation of NMDA receptors. Areas covered: A literature search was undertake...
Source: Expert Review of Neurotherapeutics - December 9, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Recently available and emerging therapeutic strategies for the acute and prophylactic management of cluster headache: a systematic review and expert opinion.
Authors: Argyriou AA, Vikelis M, Mantovani E, Litsardopoulos P, Tamburin S Abstract Introduction: Although it causes a huge burden to sufferers, cluster headache (CH), remains an undertreated condition, partly due to the absence of established acute and prophylactic treatment options. New therapeutic approaches providing fast and safe relief from CH are needed. Areas covered: A systematic review was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendation on recently published (last 5 years) papers on CH treatment. The authors also collected preliminary res...
Source: Expert Review of Neurotherapeutics - November 28, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Diagnosing and managing post-stroke aphasia.
Authors: Sheppard SM, Sebastian R Abstract INTRODUCTION: Aphasia is a debilitating language disorder and even mild forms of aphasia can negatively affect functional outcomes, mood, quality of life, social participation, and the ability to return to work. Language deficits after post-stroke aphasia are heterogeneous. AREAS COVERED: The first part of this manuscript reviews the traditional syndrome-based classification approach as well as recent advances in aphasia classification that incorporate automatic speech recognition for aphasia classification. The second part of this manuscript reviews the behavioral approac...
Source: Expert Review of Neurotherapeutics - November 25, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Exploring treatments for drooling in children with neurological disorders.
Authors: Riva A, Federici C, Piccolo G, Amadori E, Verrotti A, Striano P Abstract INTRODUCTION: Drooling represents a major problem in the every-day life of pediatric patients with neurological disorders. The significant burden, both physical and socio-psychological, of the disorder requires adequate clinical evaluation and proper management. However, treating drooling remains a challenge for clinicians. This is a review of the most up-to-date therapeutic options for the treatment of drooling in the pediatric population, hence both conservative, pharmacological, and surgical approaches are discussed. AREAS COVERED:...
Source: Expert Review of Neurotherapeutics - November 24, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Considerations when treating high-grade pediatric glioma patients with immunotherapy.
Authors: Crotty EE, Downey KM, Ferrerosa LM, Flores CT, Hegde B, Raskin S, Hwang EI, Vitanza NA, Okada H Abstract INTRODUCTION: Children with high-grade gliomas (pHGGs) represent a clinical population in substantial need of new therapeutic options given the inefficacy and toxicity of current standard-of-care modalities. Although immunotherapy has emerged as a promising modality, it has yet to elicit a significant survival benefit for pHGG patients. While preclinical studies address a variety of underlying challenges, translational clinical trial design and management also need to reflect the most updated progress and ...
Source: Expert Review of Neurotherapeutics - November 24, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

A critical review of apomorphine hydrochloride sublingual film for the treatment of Parkinson's disease 'OFF' Episodes.
Authors: Caughman CY, Factor SA Abstract Introduction: Parkinson's disease (PD) is a neurodegenerative disorder defined by its motor features. Levodopa therapy is the gold standard therapy, but over time, response is impeded by the development of motor fluctuations, including "off" episodes where PD symptoms re-emerge. Sublingual apomorphine offers a new, novel and effective therapy developed for treatment of "off" episodes. Areas Covered: Apomorphine is an old dopamine agonist developed as a subcutaneous injectable rescue therapy for "off" periods in PD that was approved in the United St...
Source: Expert Review of Neurotherapeutics - November 24, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Drug Profile: Galcanezumab for Prevention of Cluster Headache.
Authors: Mudugal D, Monteith TS Abstract Introduction Cluster headache [CH] is a severely disabling trigeminal autonomic cephalalgia [TAC]. Approximately 1 in 1,000 adults are affected by CH. Calcitonin gene related peptide [CGRP] is an important mediator in the pathophysiology of CH. Galcanezumab is a monoclonal antibody with an affinity for the CGRP peptide, FDA approved for prevention of episodic CH. Areas covered Search words queried were 'cluster headache', 'cluster headache and CGRP', 'cluster headache and galcanezumab'. Over 99 articles in Pubmed and prescribing information for galcanezumab was reviewed. Some o...
Source: Expert Review of Neurotherapeutics - November 20, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Robot Assisted Ankle Neuro-Rehabilitation: State of the art and Future Challenges.
Authors: Hussain S, Jamwal PK, Vliet PV, Brown NAT Abstract Introduction: Robot-assisted neuro-rehabilitation is gaining acceptability among the physical therapy community. The ankle is one of the most complicated anatomical joints in the human body and neurologic injuries such as stroke often result in ankle and foot disabilities. Areas covered: Robotic solutions for the ankle joint physical therapy have extensively been researched. Significant research has been conducted on the mechanism design, actuation as well as control of these ankle rehabilitation robots. Also, the experimental evaluations of these robots have...
Source: Expert Review of Neurotherapeutics - November 18, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Treating hallucinations in Parkinson's disease.
Authors: Powell A, Matar E, Lewis SJ Abstract Introduction: Hallucinations in Parkinson's disease are common, can complicate medication management and significantly impact upon the quality of life of patients and their carers. Areas covered: This review aims to examine current evidence for the management of hallucinations in Parkinson's disease. Expert opinion: Treatment of hallucinations in Parkinson's disease should be both individualised and multifaceted. Screening, education, medication review and the avoidance of common triggers are important. For well-formed visual hallucinations, acetylcholinesterase inhibitors...
Source: Expert Review of Neurotherapeutics - November 17, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Deutetrabenazine for Treatment of Involuntary Movements in Patients with Tardive Dyskinesia.
Authors: Dorfman BJ, Jimenez-Shahed J Abstract Introduction: Tardive dyskinesia (TD) is a hyperkinetic movement disorder that arises as a complication of exposure to dopamine receptor blocking agents. Vesicular monoamine transporter type 2 (VMAT2) inhibitors reduce dyskinesia by decreasing transport of monoamines, including dopamine, into presynaptic vesicles, leaving unpackaged dopamine to be metabolized by monoamine oxidase. Deutetrabenazine was adapted from an earlier VMAT2 inhibitor, tetrabenazine, by substituting three deuterium isotopes in place of three hydrogen isotopes at the site of metabolic degradation to ...
Source: Expert Review of Neurotherapeutics - November 12, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Acute symptomatic neonatal seizures, brain injury and long-term outcome: the role of neuroprotective strategies.
Authors: Pisani F, Fusco C, Nagarajan L, Spagnoli C Abstract INTRODUCTION: Neonatal seizures are frequent but underdiagnosed manifestations of acute brain dysfunction and an important contributor to unfavorable outcomes. Etiology and severity of brain injury are the single strongest outcome determinants. AREAS COVERED: The authors will discuss the prognostic role of acute symptomatic seizures versus brain injury and the main neuroprotective and neurorestorative strategies for full-term and preterm infants. EXPERT OPINION: Prolonged acute symptomatic seizures likely contribute to long-term outcomes by independent...
Source: Expert Review of Neurotherapeutics - November 12, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Metformin as a potential therapeutic for neurological disease: mobilizing AMPK to repair the nervous system.
Authors: Demaré S, Kothari A, Calcutt NA, Fernyhough P Abstract INTRODUCTION: Metformin is currently first line therapy for type 2 diabetes (T2D). The mechanism of action of metformin involves activation of AMP-activated protein kinase (AMPK) to enhance mitochondrial function (for example, biogenesis, refurbishment and dynamics) and autophagy. Many neurodegenerative diseases of the central and peripheral nervous systems arise from metabolic failure and toxic protein aggregation where activated AMPK could prove protective. Areas covered: The authors review literature on metformin treatment in Parkinson's disease...
Source: Expert Review of Neurotherapeutics - November 11, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting.
CONCLUSIONS: Almost 1 in 6 people with MS had at least some comorbidity, and nearly 1 in 6 were ≥50 years old at the time of their first DMD. As these individuals are typically excluded from clinical trials, findings illustrate the need to understand the harms and benefits of DMD use in these understudied groups. PMID: 33146570 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - November 5, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Triptanophobia in migraine: A case-control study on the causes and consequences of the non-use of triptans in chronic migraine patients.
Authors: Martínez-Pías E, García-Azorín D, Minguez-Olaondo A, Trigo J, Sierra Á, Ruiz M, Guerrero ÁL Abstract BACKGROUND: Triptanophobia is the excessive and inadequately justified concern about potential risks of triptans. We evaluated causes and consequences of non-use of triptans in chronic migraine. METHODS: Observational study with case-control design. We included chronic migraine patients firstly referred to a headache unit. Patients were cases if they were triptan naïve and controls if they had used triptans. We analyzed if non-use of triptans was justified by f...
Source: Expert Review of Neurotherapeutics - October 29, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Impact of p-tau181 and p-tau217 levels on enrolment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs.
Authors: Gauthier S, Therriault J, Pascoal T, Rosa-Neto P PMID: 33094676 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - October 24, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Current challenges in the pathophysiology, diagnosis and treatment of paroxysmal movement disorders.
Authors: Delorme C, Giron C, Bendetowicz D, Méneret A, Mariani LL, Roze E Abstract INTRODUCTION: Paroxysmal movement disorders mostly comprise paroxysmal dyskinesia and episodic ataxia, and can be the consequence of a genetic disorder or symptomatic of an acquired disease. AREAS COVERED: In this review, the authors focused on certain hot topic issues in the field: the respective contribution of the cerebellum and striatum to the generation of paroxysmal dyskinesia, the importance of striatal cAMP turnover in the pathogenesis of paroxysmal dyskinesia, the treatable causes of paroxysmal movement disorders not ...
Source: Expert Review of Neurotherapeutics - October 23, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

The comorbidities of epilepsy explained.
Authors: Mula M PMID: 33084433 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - October 22, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis.
CONCLUSION: This study will inform physicians and families on the risk profile of VGB for the treatment of epileptic spasms and will help decisions on treatment options. PMID: 33078964 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - October 21, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Minocycline for the Management of Multiple Sclerosis: Repositioning Potential, Opportunities, and Challenges.
Authors: Chauhan P, Kakkar AK, Singh H, Gautam CS Abstract INTRODUCTION: Multiple sclerosis (MS) is a chronic demyelinating inflammatory disorder with variable clinical and pathologic characteristics reflecting multiple underlying pathophysiologic mechanisms. Repositioning of existing drugs for the new indications offers several advantages including significant reduction in the cost and time of drug development and exemption from early phase clinical trials. Minocycline has been reported to exhibit immunomodulation in several pre-clinical and clinical studies through suppression of migratory inflammatory cells, modula...
Source: Expert Review of Neurotherapeutics - October 20, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Acute ischaemic stroke management: Concepts and Controversies. A narrative review.
Authors: Li KHC, Jesuthasan A, Kui C, Davies R, Tse G, Lip GYH Abstract INTRODUCTION: Amongst the 25.7 million survivors and 6.5 million deaths from stroke between 1990 and 2013, ischemic strokes accounted for approximately 70% and 50% of the cases, respectively. With patients still suffering from complications and stroke recurrence, more questions have been raised as to how we can better improve patient management. AREAS COVERED: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and Newcastle-Ottawa Scale (NOS) were adopted to ensure a comprehensive inclusion of quality lite...
Source: Expert Review of Neurotherapeutics - October 14, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Anesthesia for Electroconvulsive Therapy during the COVID-19 pandemic.
Authors: Pereira-Soares EL, Nascimento AL, da Silva JA, Nardi AE PMID: 33043717 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - October 14, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Newly approved agents for relapsing remitting multiple sclerosis: how real-world evidence compares with randomized clinical trials?
Authors: Comi G, Dalla Costa G, Moiola L Abstract INTRODUCTION: In recent years, many treatment options have become available for relapsing remitting MS. Randomized clinical trials and real-world studies are complementary sources of information, and together have the potential to offer a comprehensive understanding of the safety and efficacy profiles of each drug, a critical factor for a personalized management of the disease. AREAS COVERED: In this review, the authors provide an up-to-date review of both RCTs and real-world studies assessing the safety and efficacy profiles of recently developed disease-modifying ...
Source: Expert Review of Neurotherapeutics - October 14, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Is there value in using randomized placebo controlled trials in neuromuscular disease?
Authors: Bach JR, Chiarello G, Weiss W, Souayah N PMID: 33034226 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - October 10, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Adjunctive cenobamate for the treatment of focal onset seizures in adults with epilepsy: a critical review.
Authors: Wheless JW Abstract INTRODUCTION: Uncontrolled epilepsy has persisted despite the development of numerous antiseizure medications (ASM) over the past 25 years, and a significant need exists for more effective treatments. Cenobamate is a new ASM approved in the US for treatment of adults with focal onset seizures. AREAS COVERED: This review outlines cenobamate study results, including data in preclinical animal models through phase 2 and 3 clinical studies. Topics include mechanisms of action, pharmacokinetics, efficacy, and safety of cenobamate. Information on dosing, tolerability, and special populations ...
Source: Expert Review of Neurotherapeutics - October 9, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Practical use of pharmaceutically purified oral cannabidiol in Dravet syndrome and Lennox-Gastaut syndrome.
Authors: Lattanzi S, Zaccara G, Russo E, La Neve A, Lodi MAM, Striano P Abstract INTRODUCTION: Pharmaceutically purified oral cannabidiol (CBD) has been recently approved by the US Food and Drug Administration and European Medicines Agency as treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), which are severe and difficult-to-treat developmental and epileptic encephalopathies with onset in early childhood. AREAS COVERED: This review will critically review the pharmacokinetic properties of CBD, the interactions with antiseizure and non-antiseizure medications, and the main ...
Source: Expert Review of Neurotherapeutics - October 8, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian Chronic Migraine Group.
Authors: Sacco S, Russo A, Geppetti P, Grazzi L, Negro A, Tassorelli C, Tedeschi G, Martelletti P Abstract INTRODUCTION: OnabotulinumtoxinA (OBT-A) and monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway are two of the few treatments that ameliorate chronic migraine (CM) in randomized controlled trials and real-life studies. Separate clinical practice guidelines have been developed for the management of CM with OBT-A or CGRP-targeting mAbs. AREAS COVERED: Considering the concomitant availability of OBT-A and CGRP-targeting mAbs as therapeutic treatment options, Italian migraine...
Source: Expert Review of Neurotherapeutics - September 30, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

From QAAPAPLE 1 to QAAPAPLE 2: How do we move from one algorithm to another one with Long acting antipsychotics (LAIs).
CONCLUSIONS: Since its initial publication, the QAAPAPLE algorithm has been updated to guide clinicians on the use of LAIs. The new algorithm has also been assessed outside Canada to test its generalisability worldwide, and indicated its flexibility, efficiency and user-friendliness in order to guide clinicians on the use of LAIs. PMID: 32962466 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - September 24, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

The severity of Obsessive-Compulsive Symptoms in Tourette syndrome and its Relationship with Premonitory Urges: a Meta-Analysis.
CONCLUSION: There was a mild positive correlation between the PUs and OCS in patients with TS. The severity of OCS in TS patients was mild to moderate and positively predicted by the severity of tic symptoms. PMID: 32954857 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - September 22, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

The Emerging Role of Psilocybin and MDMA in the Treatment of Mental Illness.
Authors: Gill H, Gill B, Chen-Li D, El-Halabi S, Rodrigues NB, Cha DS, Lipsitz O, Lee Y, Rosenblat JD, Majeed A, Mansur RB, Nasri F, Ho R, McIntyre RS Abstract INTRODUCTION: Mental illness has a chronic course of illness with a number of clinical manifestations. Affected individuals experience significant functional, emotional, cognitive and/or behavioral impairments. The growing prevalence of mental illness has been associated with significant social and economic costs. Indeed, the economic burden of mental illness is estimated to exceed $1.8 trillion USD over the next 30 years. A significant number of individuals af...
Source: Expert Review of Neurotherapeutics - September 22, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

The therapeutic effect of habit reversal training for Tourette syndrome: a meta-analysis of randomized control trials.
CONCLUSION: Overall, the authors found a small to medium effect size for the efficacy of HRT. As the most promising behavioral therapy, they conclude that HRT is effective for the treatment of patients with tic disorders. Further high-quality RCTs are needed to determine the efficacy of HRT compared with that of medications. PMID: 32948114 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - September 20, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Sensory Stimulation Programs in Dementia: a Systematic Review of Methods and Effectiveness.
Authors: Pinto JFFTO, Dores AAMDR, Geraldo APA, Peixoto BMRTB, Barbosa MFDS Abstract INTRODUCTION: Dementia is characterized by the presence of cognitive decline and can lead to sensory-perceptual alterations, compromising the functionality in activities of daily living. The main objective of this work is to review the characteristics of sensory stimulation programs in dementia and its effectiveness. AREAS COVERED: Studies were identified through a literature search, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Cochrane Collaboration Guidelines. Twenty studies we...
Source: Expert Review of Neurotherapeutics - September 18, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Diagnostic challenges in metabolic myopathies.
Authors: Angelini C, Marozzo R, Pegoraro V, Sacconi S Abstract INTRODUCTION: Metabolic myopathies comprise a clinically etiological diverse group of disorders caused by defects in cellular energy metabolism including the breakdown of carbohydrates and fatty acids, which include glycogen storage diseases and fatty acid oxidation disorders. Their wide clinical spectrum ranges from infantile severe multisystemic disorders to adult-onset myopathies. To suspect in adults these disorders, clinical features such as exercise intolerance and recurrent myoglobinuria need investigation while another group presents fixed weakness...
Source: Expert Review of Neurotherapeutics - September 18, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Emerging Therapies in Friedreich's Ataxia.
Authors: Zesiewicz TA, Hancock J, Ghanekar SD, Kuo SH, Dohse CA, Vega J Abstract INTRODUCTION: Friedreich's ataxia (FRDA) is a progressive, neurodegenerative disease that results in gait and limb ataxia, diabetes, cardiac hypertrophy, and scoliosis. At the cellular level, FRDA results in the deficiency of frataxin, a mitochondrial protein that plays a vital role in iron homeostasis and amelioration of oxidative stress. No cure currently exists for FRDA, but exciting therapeutic developments which target different parts of the pathological cascade are on the horizon. AREAS COVERED: Areas covered include past and eme...
Source: Expert Review of Neurotherapeutics - September 12, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Combination therapy in migraine: asset or issue?
Authors: Martelletti P PMID: 32896181 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - September 9, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Autologous Hematopoietic Stem Cell Transplantation in Neurological Disorders: Current Approach and Future Directions.
Authors: Das J, Sharrack B, Snowden JA Abstract INTRODUCTION: Autologous hematopoietic stem cell transplantation (AHSCT) has become increasingly popular in recent years as an effective treatment of immune mediated neurological diseases. Treatment related mortality has significantly reduced primarily through better patient selection, optimization of transplant technique and increased center experience. Area covered: Multiple sclerosis is the main indication, but people with neuromyelitis optica spectrum disorder, stiff person spectrum disorder, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis and ot...
Source: Expert Review of Neurotherapeutics - September 8, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Neurotechnologies as tools for cognitive rehabilitation in stroke patients.
Authors: Draaisma LR, Wessel MJ, Hummel FC Abstract Introduction Cognitive impairments are one of the most common remaining symptoms after a stroke. The use of neurotechnologies to enhance cognitive performance is a rapidly emerging field with encouraging results. Areas covered Here, the authors empirically review the respective literature and critically discuss the technologies that are currently most often used for cognitive enhancement in stroke patients, which are computerized cognitive training, virtual reality, non-invasive brain stimulation and brain-computer interfaces. The authors describe their advantages/di...
Source: Expert Review of Neurotherapeutics - September 6, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Lightening the mood: evidence for blue light exposure in the treatment of post-concussion depression.
Authors: Killgore WDS PMID: 32865054 [PubMed - as supplied by publisher] (Source: Expert Review of Neurotherapeutics)
Source: Expert Review of Neurotherapeutics - September 1, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Can Mindfulness-Based Interventions Benefit People with Dementia? Drawing on The Evidence from a Systematic Review in Populations with Cognitive Impairments.
Authors: Chan J, Leung DKY, Walton H, Wong GHY, Spector A Abstract INTRODUCTION: Non-pharmacological interventions that promote quality of life in people with dementia are urgently needed. To accelerate development, evidence-based psychotherapies used in other populations can be considered. Mindfulness-based interventions with standardised protocols, namely mindfulness-based cognitive therapy (MBCT) and mindfulness-based stress reduction (MBSR), may be effective in people with dementia, although tailoring for cognitive impairment may be needed. Evidence from other cognitive disorders can inform research. AREAS COVE...
Source: Expert Review of Neurotherapeutics - August 28, 2020 Category: Neurology Tags: Expert Rev Neurother Source Type: research